Exclusive Summary

• A classic first-line SSRI antidepressant listed on the WHO Essential Medicines List, targeting a massive global market of over 280 million depression patients.
• With the originator patent expired and 20mg being the standard adult dose, it is a highly mature, high-frequency prescription product requiring no market education.
• Leverages China's vertically integrated API+FDF supply chain to offer highly competitive manufacturing costs and lucrative profit margins for overseas distributors.
• Comes with comprehensive CTD registration dossiers and complete bioequivalence (BE) data compliant with major pharmacopeias, enabling rapid localized registration and commercialization.